⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523998 | 0.76 | — | — | |
| SCHEMBL558617 | 0.74 | — | — | |
| SCHEMBL5904912 | 0.69 | PPARG (0.33) | — | |
| SCHEMBL2067460 | 0.69 | KDM4E (0.34) | — | |
| SCHEMBL2650715 | 0.68 | ALDH1A1 (0.38) | — | |
| SCHEMBL2067407 | 0.66 | KDM4E (0.32) | — | |
| SCHEMBL2066991 | 0.65 | — | — | |
| SCHEMBL2067035 | 0.65 | — | — | |
| SCHEMBL11213696 | 0.64 | NOS3 (0.39) | — | |
| SCHEMBL166316 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | claimed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | claimed |
| US-7250443-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2007-07-31 | — | — | US | claimed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | claimed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | claimed |
| US-6989382-B2 | Carbocycle based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| EP-1556355-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1537099-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2005-06-08 | — | — | EP | claimed |
| US-20040138273-A1 | Carbocycle based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2004-07-15 | — | — | US | claimed |
| WO-2004037791-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004018455-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | claimed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | claimed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | claimed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | claimed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | claimed |
| WO-2018178194-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF BRAIN INJURIES OR DEMYELINATING DISORDERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2018-10-04 | — | — | WO | disclosed |
| US-7671049-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090074886-A1 | GSK-3 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2009-03-19 | — | — | US | disclosed |
| EP-1653970-A4 | GSK-3 INHIBITORS AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1237880-B1 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-7250443-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1490093-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIA | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060135534-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-06-22 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| EP-1653970-A2 | GSK-3 INHIBITORS AND USES THEREOF | CHIRON CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| US-6989382-B2 | Carbocycle based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-01-24 | — | — | US | disclosed |
| EP-1607396-A1 | Bicyclic inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2005-12-21 | — | — | EP | disclosed |
| US-6949547-B2 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050203059-A1 | Methods and compositions for treatment of ischemia | HARRISON STEPHEN D (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1240168-B1 | BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORP (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1556355-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1537099-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005039485-A2 | GSK-3 INHIBITORS AND USES THEREOF | CHIRON CORPORATION (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050054663-A1 | Bone disorders; osteoporosis | CHIRON CORPORATION | 2005-03-10 | — | — | US | disclosed |
| EP-1490093-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIA | CHIRON CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6800632-B2 | FOR TREATMENT OF DISORDERS MEDIATED BY GSK3 ACTIVITY, SUCH AS DIABETES, ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS, OBESITY, ATHEROSCLEROTIC CARDIOVASCULAR DISEASE | CHIRON CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-20040138273-A1 | Carbocycle based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2004-07-15 | — | — | US | disclosed |
| WO-2004037791-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004018455-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20030216574-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | NUSS JOHN M (US) | 2003-11-20 | — | — | US | disclosed |
| WO-2003074072-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIA | CHIRON CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
| US-6608063-B2 | For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes | CHIRON CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030008866-A1 | Bicyclic inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-01-09 | — | — | US | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-1240168-A1 | BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1237880-A2 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001044206-A9 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORP (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| US-20010044436-A1 | Bicyclic inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2001-11-22 | — | — | US | disclosed |
| US-20010034051-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2001-10-25 | — | — | US | disclosed |
| WO-2001044246-A1 | BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044206-A1 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |